Compare Infosys Limited (INFY) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Infosys Limited trades at $10.75 (market cap $41.74B), while Nuvation Bio Inc. Class A Common Stock trades at $5.03 (market cap $1.74B). The key difference: Infosys Limited is far larger — about 24× Nuvation Bio Inc. Class A Common Stock's market cap, and Infosys Limited pays a 4.89% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Nuvation Bio Inc. Class A Common Stock for 1 Days on average.
| INFY | NUVB | |
|---|---|---|
Market Cap | $41.74B | $1.74B |
Volume | 31,354,285 | 9,289,619 |
Sector | Technology | Health |
52-Week High | $20.22 | $9.54 |
52-Week Low | $10.49 | $3.41 |
Typical Hold Time | 27 Days | 1 Days |
Enterprise Value | $39.48B | $1.33B |
Dividend Yield | 4.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.78, up 2.18% today, with a bearish technical signal from moving averages. The company reported revenue of $19.28B in 2025 with a net income margin of 16.37%, and recent earnings show mixed results with a beat in Q1 2026 but a miss in Q2 2026. Positive news includes strategic AI collaborations with Columbia University and ABN Amro, highlighting growth initiatives in technology services.
The outlook is cautiously optimistic with a consensus price target of $11.48, offering potential upside. Risks include competitive pressures in IT services and volatile cash flow trends, with net cash flow turning negative in 2026. Analyst sentiment is mixed, with 35% buy ratings, but institutional activity shows increased holdings, supporting a stable foundation for recovery.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
